Literature DB >> 25595706

Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey.

E M Trecarichi1, L Pagano2, A Candoni3, D Pastore4, C Cattaneo5, R Fanci6, A Nosari7, M Caira2, A Spadea8, A Busca9, N Vianelli10, M Tumbarello11.   

Abstract

A prospective cohort study was conducted in nine hematology wards at tertiary care centres or at university hospitals located throughout Italy from January 2009 to December 2012. All of the cases of bacterial bloodstream infection (BBSI) occurring in adult patients with hematologic malignancies were included. A total of 668 bacterial isolates were recovered in 575 BBSI episodes. Overall, the susceptibility rates of Gram-negative bacteria were 59.1% to ceftazidime, 20.1% to ciprofloxacin, 79.1% to meropenem, 85.2% to amikacin, 69.2% to gentamicin and 69.8% to piperacillin/tazobactam. Resistance to third-generation cephalosporins was found in 98/265 (36.9%) of Enterobacteriaceae isolates. Among Klebsiella pneumoniae strains, 15/43 (34.9%) were resistant to carbapenems. Of 66 Pseudomonas aeruginosa isolates, 46 (69.7%) were multidrug resistant. Overall, the susceptibility rates of Gram-positive bacteria were 97.4% to vancomycin and 94.2% to teicoplanin. Among the monomicrobial cases of BBSI, the 21-day mortality rate was significantly higher for those caused by Gram-negative bacteria compared to those caused by Gram-positive bacteria (47/278, 16.9% vs. 12/212, 5.6%; p < 0.001). Among Gram-negative bacteria, the mortality rate was significantly higher for BBSI caused by K. pneumoniae, P. aeruginosa, and Acinetobacter baumannii. Our results confirm the recently reported shift of prevalence from Gram-positive to Gram-negative bacteria as causative agents of BBSIs among patients with hematologic malignancies and highlight a worrisome increasing frequency in antimicrobial resistance among Gram-negative bacteria.
Copyright © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial resistance; bacterial bloodstream infections; epidemiology; hematologic cancer; mortality; multidrug resistance

Mesh:

Year:  2014        PMID: 25595706     DOI: 10.1016/j.cmi.2014.11.022

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  51 in total

1.  Colonization With Levofloxacin-resistant Extended-spectrum β-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients.

Authors:  Michael J Satlin; Kalyan D Chavda; Thomas M Baker; Liang Chen; Elena Shashkina; Rosemary Soave; Catherine B Small; Samantha E Jacobs; Tsiporah B Shore; Koen van Besien; Lars F Westblade; Audrey N Schuetz; Vance G Fowler; Stephen G Jenkins; Thomas J Walsh; Barry N Kreiswirth
Journal:  Clin Infect Dis       Date:  2018-11-13       Impact factor: 9.079

2.  Changes in bacterial epidemiology and antibiotic resistance among veterans with spinal cord injury/disorder over the past 9 years.

Authors:  Margaret A Fitzpatrick; Katie J Suda; Nasia Safdar; Stephen P Burns; Makoto M Jones; Linda Poggensee; Swetha Ramanathan; Charlesnika T Evans
Journal:  J Spinal Cord Med       Date:  2017-02-15       Impact factor: 1.985

3.  Antimicrobial Stewardship in Hematological Patients at the intensive care unit: a global cross-sectional survey from the Nine-i Investigators Network.

Authors:  Jordi Rello; Cristina Sarda; Djamel Mokart; Kostoula Arvaniti; Murat Akova; Alexis Tabah; Elie Azoulay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-11-09       Impact factor: 3.267

Review 4.  Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies.

Authors:  Stephanie M Pouch; Michael J Satlin
Journal:  Virulence       Date:  2016-07-28       Impact factor: 5.882

Review 5.  Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.

Authors:  Xiao Jun Wang; Alexandre Chan
Journal:  Curr Oncol Rep       Date:  2017-03       Impact factor: 5.075

Review 6.  Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients.

Authors:  Michael J Satlin; Thomas J Walsh
Journal:  Transpl Infect Dis       Date:  2017-10-25       Impact factor: 2.228

7.  Bloodstream Infections and Delayed Antibiotic Coverage Are Associated With Negative Hospital Outcomes in Hematopoietic Stem Cell Transplant Recipients.

Authors:  Joyce Ji; Jeff Klaus; Jason P Burnham; Andrew Michelson; Colleen A McEvoy; Marin H Kollef; Patrick G Lyons
Journal:  Chest       Date:  2020-06-17       Impact factor: 9.410

8.  Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.

Authors:  C Gudiol; A Albasanz-Puig; J Laporte-Amargós; N Pallarès; A Mussetti; I Ruiz-Camps; P Puerta-Alcalde; E Abdala; C Oltolini; M Akova; M Montejo; M Mikulska; P Martín-Dávila; F Herrera; O Gasch; L Drgona; H Paz Morales; A-S Brunel; E García; B Isler; W V Kern; I Morales; G Maestro-de la Calle; M Montero; S S Kanj; O R Sipahi; S Calik; I Márquez-Gómez; J I Marin; M Z R Gomes; P Hemmatti; R Araos; M Peghin; J L Del Pozo; L Yáñez; R Tilley; A Manzur; A Novo; J Carratalà
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

9.  Prognostic factors and scoring model of hematological malignancies patients with bloodstream infections.

Authors:  Yishu Tang; Qian Cheng; Qing Yang; Jing Liu; Di Zhang; Wei Cao; Qingxia Liu; Tianyi Zhou; Huiqi Zeng; Li Zhou; QinJin Wang; Huan Wei; Xin Li
Journal:  Infection       Date:  2018-05-16       Impact factor: 3.553

Review 10.  The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies.

Authors:  Thomas M Baker; Michael J Satlin
Journal:  Leuk Lymphoma       Date:  2016-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.